ArticleBrain & spine2024
Breaking boundaries: A rare case of glioblastoma with uncommon extraneural metastases: A case report and literature review.
Article in Brain & spine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diffuse bone-marrow metastasis of grade 4 isocitrate dehydrogenase-mutant astrocytoma associated with hematological abnormalities: Gliomatosis of the bone marrow.Surgical neurology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extraneural metastases (ENM) from glioblastoma (GBM) remain extremely rare with only a scarce number of cases described in the literature. The lack of cases leads to no consensus on the optimal treatment and follow-up of these patients. Research question: Do patient or tumor characteristics describe risk factors for ENM in GBM patients, and is it possible to identify mechanisms of action? Material and methods: This study presents a 55-year-old man with diagnosed GBM who was referred to a CT due to reduced general condition and mild back pain which revealed extensive systemic metastases. A literature review was conducted to identify potential patient or tumor characteristics that may serve as risk factors for metastasis. Results: ENM from GBM are likely underreported, with limited examples in the literature and low survival rates of only a few months. Certain clinical and histopathological factors, such as male sex, younger age, temporal lobe location, and specific biological markers, have been associated with a higher likelihood of metastasis formation. Bone and/or bone marrow metastases are the most common sites. Despite various treatment regimens being attempted, there is no consensus on the optimal therapeutic approach for this patient group. Conclusion: Clinical and histopathological factors can aid clinicians in recognizing the potential for ENM in GBM patients. Our review identifies some of the possible patient- and tumor-related risk factors. However, further research is crucial to identify specific molecular markers and elucidate the underlying biological mechanisms that is essential for development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.